Crossmark Global Holdings Inc. Sells 46 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Crossmark Global Holdings Inc. lowered its stake in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 0.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,404 shares of the medical instruments supplier’s stock after selling 46 shares during the period. Crossmark Global Holdings Inc.’s holdings in West Pharmaceutical Services were worth $2,255,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at $300,250,000. Artisan Partners Limited Partnership boosted its holdings in West Pharmaceutical Services by 23.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock valued at $690,530,000 after acquiring an additional 369,792 shares during the last quarter. APG Asset Management US Inc. acquired a new stake in West Pharmaceutical Services in the fourth quarter worth about $88,227,000. TD Asset Management Inc raised its holdings in West Pharmaceutical Services by 38.4% during the 4th quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock worth $232,244,000 after purchasing an additional 183,153 shares during the last quarter. Finally, Findlay Park Partners LLP lifted its position in West Pharmaceutical Services by 65.2% during the 4th quarter. Findlay Park Partners LLP now owns 457,306 shares of the medical instruments supplier’s stock valued at $161,027,000 after purchasing an additional 180,415 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.1 %

Shares of NYSE WST opened at $314.76 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $310.42 and a 52-week high of $415.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The stock has a market cap of $22.93 billion, a P/E ratio of 41.53, a P/E/G ratio of 5.57 and a beta of 1.01. The firm has a 50 day moving average price of $361.29 and a 200 day moving average price of $362.79.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The company had revenue of $695.40 million for the quarter, compared to analysts’ expectations of $670.62 million. During the same period last year, the firm posted $1.98 earnings per share. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. Analysts expect that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on WST. KeyCorp lifted their price target on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 13th. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. Finally, UBS Group dropped their target price on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and a consensus price target of $435.20.

Get Our Latest Stock Report on West Pharmaceutical Services

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the transaction, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at $469,695.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now directly owns 1,309 shares in the company, valued at approximately $469,695.38. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.